Topic Hub
24 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 24 of 24 clinical reviews.
A clinician-reviewed deep dive into how tesamorelin (Egrifta) affects appetite and food cravings, drawing on primary trial data, mechanism-of-action science, and practical dosing guidance for HIV-associated lipodystrophy.
Read clinical reviewA clinician-level review of how tesamorelin (Egrifta) interacts with autoimmune disease, covering IGF-1 immune signaling, contraindications, monitoring protocols, and safety data from key trials.
Read clinical reviewA physician-level review of how tesamorelin affects bone mineral density, bone turnover markers, and fracture risk in HIV-associated lipodystrophy, with primary-literature citations and clinical guidance.
Read clinical reviewA board-reviewed, primary-literature analysis of the tesamorelin cancer risk signal: what the clinical trials show, what the IGF-1 biology means, and how prescribers should monitor patients receiving Egrifta.
Read clinical reviewA comprehensive, physician-reviewed guide to tesamorelin's effects on cognition, including clinical trial data, mechanisms, and what patients and providers need to know about Egrifta and brain health.
Read clinical reviewA physician-level comparison of compounded tesamorelin versus branded Egrifta SV, covering FDA approval status, pharmacokinetics, clinical trial data, cost, and prescribing guidance for HIV-associated lipodystrophy.
Read clinical reviewA GRADE-graded review of tesamorelin (Egrifta) clinical evidence for HIV-associated lipodystrophy, covering key trials, effect sizes, safety, and current guideline recommendations.
Read clinical reviewA physician-reviewed guide to tesamorelin's effects on hair and skin, covering clinical trial data, GH-axis mechanisms, patient monitoring, and management of dermatologic adverse effects.
Read clinical reviewA physician-reviewed deep-dive into how tesamorelin (Egrifta) affects liver function, including ALT/AST changes, hepatic fat, and NAFLD risk in HIV-associated lipodystrophy patients.
Read clinical reviewA physician-reviewed deep dive into how tesamorelin (Egrifta) affects mood, cognition, and mental health in HIV-associated lipodystrophy, with primary-literature citations and clinical guidance.
Read clinical reviewA physician-reviewed guide to how tesamorelin (Egrifta) affects metabolism, energy expenditure, and body composition in HIV-associated lipodystrophy, with primary-literature citations and dosing guidance.
Read clinical reviewA physician-reviewed deep dive into tesamorelin microdosing protocols, standard FDA-approved dosing, clinical trial data, and what off-label dose reductions mean for HIV-associated lipodystrophy management.
Read clinical reviewEvidence-based muscle preservation strategies for patients on tesamorelin (Egrifta), covering mechanisms, dosing, resistance training protocols, nutrition, and monitoring. Reviewed by the HealthRX medical team.
Read clinical reviewA clinician-level guide to diagnosing and resolving tesamorelin plateau and non-response in HIV-associated lipodystrophy, with primary-literature citations and a practical decision framework.
Read clinical reviewA clinician-level review of tesamorelin (Egrifta) in post-bariatric patients: mechanism, visceral fat data, GH-axis physiology after surgery, dosing, monitoring, and off-label considerations.
Read clinical reviewA physician-level guide to the tesamorelin pre-surgery hold window: when to stop Egrifta before surgery, why GH-axis activity demands perioperative caution, and how to restart therapy safely after the procedure.
Read clinical reviewWhat happens to visceral fat, IGF-1, and metabolic markers when tesamorelin is discontinued? A physician-reviewed clinical breakdown of rebound kinetics, risk factors, and evidence-based mitigation strategies.
Read clinical reviewA physician-level review of tesamorelin's effects on kidney function, including GFR data, IGF-1 mechanisms, renal hemodynamics, and safety guidance for patients with HIV-associated lipodystrophy.
Read clinical reviewA clinician-level guide to safely restarting tesamorelin (Egrifta) after acute illness, covering pharmacology, timing, dose re-titration, monitoring, and special populations in HIV-associated lipodystrophy.
Read clinical reviewA clinician-level review of how seasonal factors, including temperature, immune cycling, metabolic shifts, and patient adherence patterns, affect tesamorelin (Egrifta) therapy for HIV-associated lipodystrophy, with dosing guidance and monitoring recommendations.
Read clinical reviewA physician-reviewed analysis of how tesamorelin (Egrifta) affects sexual function in people with HIV-associated lipodystrophy, including mechanisms, trial data, and clinical guidance.
Read clinical reviewA clinical deep-dive into how tesamorelin (Egrifta) affects sleep architecture, slow-wave sleep, GH pulsatility, and sleep quality in HIV-associated lipodystrophy and off-label contexts. Reviewed by the HealthRX medical team.
Read clinical reviewMD/PharmD-level guide to traveling with tesamorelin (Egrifta): cold-chain transport, TSA rules, dose-timing adjustments across time zones, and injection technique on the road.
Read clinical reviewA physician-reviewed, week-by-week guide to tesamorelin (Egrifta) during the first 30 days: injection technique, timeline of visceral fat reduction, side effects, and what lab changes to monitor.
Read clinical review